U.S. Pathology Laboratories Market - Databook 2025 to 2034

The U.S. pathology laboratories market size was evaluated at USD 101.67 Billion in 2024 and is expected to grow around USD 209 billion by 2034, registering a CAGR of 7.47% from 2025 to 2034.

Highlights of the U.S. Pathology Laboratories Market

• By type, the hospital-based segment holds a dominant presence in the pathology laboratories market in 2024.
• By type, the diagnostic chains segment is projected to experience the highest growth rate in the U.S. pathology laboratories market between 2025 and 2034.
• By testing service, the clinical tests & general physiological segment holds a dominant presence in the pathology laboratories market in 2024.
• By testing service, the esoteric tests segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By end-use, the physician referrals segment holds a dominant presence in the pathology laboratories market in 2024.
• By end-use, the corporate segment is anticipated to grow with the highest CAGR in the U.S. pathology laboratories market during the studied years.

Industry Valuation and Growth Rate Projection

The U.S. pathology laboratories market is defined as the foundation of modern healthcare, playing a vital role in disease prognosis, diagnosis, and treatment planning. With the growing burden of chronic diseases such as diabetes, cancer, and cardiovascular disorders, the requirement for accurate and on-time diagnostics has surged. Pathology labs offer vital insights into disease pathology, permitting physicians to make informed decisions about specific patient care. The rise of precision medicine, which depends on genetic and molecular diagnostics, has thus promoted the importance of pathology laboratories.

What Are the Market Trends in the U.S. Pathology Laboratories Market?

• The market trends in the U.S. pathology laboratories market are characterized by increasing demand for diagnostic testing and an increasing emphasis on early detection of diseases, as well as increasing commercialization of lab chains.
• The growing burden of chronic diseases such as cardiovascular ailments and cancer is a major contributor to the pathology market, as such conditions demand extensive diagnostic testing.
• There is an increasing emphasis on early disorder detection via advanced diagnostic tests and routine screenings, which is leading to an increased need for pathology services.
• Diagnostic chains are enduring significant growth, providing a convenient and accessible alternative for patients looking for diagnostic testing.
• The digital pathology market in the United States is experiencing high acceptance rates, driven by well-known healthcare infrastructure as well as high per capita healthcare expenditure.

What Are the Restraints in the U.S. Pathology Laboratories Market?

• Restraints in the U.S. pathology laboratories market include a lack of adequately trained personnel and an increasingly competitive market with several new players building diagnostic laboratory chains across the United States.
• There is a perceived lack of pathologists in the United States, which can provide difficulties in service delivery and staffing. This lack is compelled by the increasing requirement for pathology services due to factors such as an older population and the growing incidence of chronic diseases.
• The market is becoming more challenging, with larger key players driving consolidation and acquiring smaller labs. This can contribute to decreased acceptance of specialized testing in certain zones, mainly in rural or underserved communities.

What Are the Opportunities in the U.S. Pathology Laboratories Market?

• Opportunities in the U.S. pathology laboratories market are connected to the increasing healthcare provider focus on early diagnostics and the need for rapid testing.
• The aim of tailoring treatments to specific patients creates a remarkable opportunity for pathology labs to grasp their expertise in diagnostics for customized treatment plans.
• The advancement of fast and accurate diagnostic tests for infectious disorders, like syndromic panels and multiplex assays, is driving expansion in the virology and microbiology segments.
• The focus on early diagnosis of disorders, coupled with developments in diagnostics and pathology, is creating a strong requirement for pathology services.

Recent Developments in the U.S. Pathology Laboratories Market

• Alverno Laboratories started the latest digital pathology services from Royal Philips, a global contributor to health technology. The laboratory network will utilize Philips IntelliSite Pathology Solution to help and support the usage of digital technology to diagnose pathology cases digitally and interpret histology, instead of using a microscope, with the target of improving laboratory efficiency, quality, and patient care and safety.